Can Functionally Mature Islet β-Cells be Derived from Pluripotent Stem Cells? A Step Towards Ready-To-Use β-Cells in Type 1 Diabetes

Author(s): Bishnu K. Khand*, Ramesh R. Bhonde

Journal Name: Current Stem Cell Research & Therapy

Volume 16 , Issue 3 , 2021

Become EABM
Become Reviewer
Call for Editor


Pluripotent Stem Cells [PSCs] are emerging as an excellent cellular source for the treatment of many degenerative diseases such as diabetes, ischemic heart failure, Alzheimer’s disease, etc. PSCderived pancreatic islet β-cells appear to be a promising therapy for type 1 diabetic patients with impaired β-cell function. Several protocols have been developed to derive β-cells from PSCs. However, these protocols produce β-like cells that show low glucose stimulated insulin secretion (GSIS) function and mirror GSIS profile of functionally immature neonatal β-cells. Several studies have documented a positive correlation between the sirtuins (a family of ageing-related proteins) and the GSIS function of adult β-cells. We are of the view that the GSIS function of PSC-derived β-like cells could be enhanced by improving the function of sirtuins in them. Studying the sirtuin expression and activation pattern during the β-cell development and inclusion of the sirtuin activators and inhibitor cocktail (specific to a developmental stage) in the present protocols may help us derive functionally mature, ready-to-use β- cells in-vitro making them suitable for transplantation in type 1 diabetes.

Keywords: Pluripotent Stem Cells (PSCs), Pancreatic islet β-cells, Glucose stimulated insulin secretion (GSIS), Sirt1, Type 1 diabetes, Uncoupling Protein2 (UCP2).

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2021
Published on: 21 June, 2020
Page: [231 - 237]
Pages: 7
DOI: 10.2174/1574888X15666200621171726
Price: $65

Article Metrics

PDF: 31